公开(公告)号：WO2004026822A3

公开(公告)日：2004-05-06

申请号：PCT/US0329018

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  FEENSTRA MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  A61K31/401 ,  A61K31/4439 ,  A61K31/506

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的式I化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖症，动脉粥样硬化和 各种免疫调节疾病。 或其药学上可接受的盐或前药，其中X，R，R 1，R 2和R 3具有说明书中给出的定义。

公开(公告)号：WO0128979A3

公开(公告)日：2001-12-27

申请号：PCT/US0027938

申请日：2000-10-10

Applicant: ABBOTT LAB

Inventor： MARING CLARENCE J ,  GIRANDA VINCENT L ,  KEMPF DALE J ,  STOLL VINCENT S ,  SUN MINGHUA ,  ZHAO CHEN ,  GU YU GUI ,  WANG GARY T ,  KRUEGER ALLAN C ,  CHEN YUANWEI ,  DEGOEY DAVID A ,  GRAMPOVNIK DAVID J ,  KATI WARREN M ,  KENNEDY APRIL L ,  LIN ZHEN ,  MADIGAN DONALD L ,  MUCHMORE STEVEN W ,  SHAM HING L ,  STEWART KENT D ,  WANG SHELDON ,  YEUNG MING C

IPC: A61K31/195 ,  C07C233/48 ,  C07C237/24 ,  C07C271/22 ,  C07C271/24 ,  C07C279/16 ,  C07D233/54 ,  C07D263/32 ,  C07D307/24 ,  C07D317/30 ,  C07D405/04 ,  A61K31/325 ,  A61K31/34 ,  A61K31/415 ,  A61K31/42 ,  A61P31/00

CPC classification number: C07D233/64 ,  C07B2200/07 ,  C07B2200/09 ,  C07C233/48 ,  C07C237/24 ,  C07C271/22 ,  C07C271/24 ,  C07C279/16 ,  C07C2601/08 ,  C07C2601/10 ,  C07D263/32 ,  C07D307/24 ,  C07D317/30 ,  C07D405/04

Abstract: Disclosed are compounds of formula (I), (II) or (III) which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

Abstract translation: 公开了可用于抑制致病微生物，特别是流感神经氨酸酶的神经氨酸酶的式（I），（II）或（III）的化合物。 还公开了用于预防和治疗由具有神经氨酸酶的微生物引起的疾病的组合物和方法，用于制备这些方法中使用的化合物和合成中间体的方法。

公开(公告)号：MY136181A

公开(公告)日：2008-08-29

申请号：MYPI20014939

申请日：2001-10-24

Applicant: ABBOTT LAB

Inventor： CLAIBORNE AKIYO K ,  SULLIVAN GERARD M ,  TONG YUNSONG ,  WANG GARY T ,  WANG LE ,  WANG XILU ,  WANG WEIBO ,  GWALTNEY STEPHEN L II ,  HASVOLD LISA A ,  LI QUN ,  LI TONGMEI ,  LIN NAN-HORNG ,  MANTEI ROBERT A ,  ROCKWAY TODD W ,  SHAM HING L

IPC: A61K31/4164 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/4709 ,  A61P35/00 ,  A61P43/00 ,  C07D233/54 ,  C07D233/64 ,  C07D277/20 ,  C07D277/30 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: SUBSTITUTED IMIDAZOLES AND THIAZOLES HAVING THE FORMULA I ARE USEFUL FOR INHIBITING FARNESYLTRANSFERASE.ALSO DISCLOSED ARE FARNESYLTRANSFERASE-INHIBITING COMPOSITIONS AND METHODS OF INHIBITING FARNESYLTRANSFERASE IN A PATIENT .

公开(公告)号：CA2393271C

公开(公告)日：2007-12-11

申请号：CA2393271

申请日：1991-11-15

Applicant: ABBOTT LAB

Inventor： KEMPF DALE J ,  NORBECK DANIEL W ,  WITTENBERGER STEVEN J ,  CODACOVI LYNN M ,  SHAM HING L ,  PLATTNER JACOB J ,  ZHAO CHEN

IPC: A61K31/42 ,  C07D277/28 ,  A61K31/421 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61K31/435 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K38/00 ,  A61P31/12 ,  A61P31/18 ,  A61P43/00 ,  C07C53/134 ,  C07C211/00 ,  C07C215/18 ,  C07C215/20 ,  C07C215/28 ,  C07C215/30 ,  C07C215/80 ,  C07C219/18 ,  C07C233/40 ,  C07C237/10 ,  C07C237/22 ,  C07C269/04 ,  C07C271/02 ,  C07C271/16 ,  C07C271/20 ,  C07C271/22 ,  C07C271/34 ,  C07C275/24 ,  C07D20060101 ,  C07D213/00 ,  C07D213/26 ,  C07D213/30 ,  C07D213/34 ,  C07D213/36 ,  C07D213/40 ,  C07D213/54 ,  C07D213/56 ,  C07D213/61 ,  C07D213/75 ,  C07D213/79 ,  C07D215/20 ,  C07D233/54 ,  C07D233/84 ,  C07D235/14 ,  C07D235/16 ,  C07D237/10 ,  C07D239/26 ,  C07D241/12 ,  C07D261/08 ,  C07D261/12 ,  C07D263/20 ,  C07D263/32 ,  C07D277/20 ,  C07D277/24 ,  C07D277/30 ,  C07D277/32 ,  C07D277/34 ,  C07D277/36 ,  C07D277/40 ,  C07D277/42 ,  C07D277/56 ,  C07D295/02 ,  C07D295/13 ,  C07D295/205 ,  C07D295/215 ,  C07D303/36 ,  C07D307/34 ,  C07D307/42 ,  C07D307/66 ,  C07D333/16 ,  C07D333/36 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D521/00 ,  C07K1/113 ,  C07K5/06 ,  C07K5/065 ,  C07K5/08 ,  C07K14/81

Abstract: A retroviral protease inhibiting compound is diclosed. The compound is of the formula (see formula I) wherein R1 is hydrogen and R2 and R3 are independently selected from C6-aryl-C1-to-C6-alkyl, C9-to-C10-aryl-C1-to-C6-alkyl, C3-to-C7- cycloalkyl-C1-to-C6-alkyl and (heterocyclic)-C1-to-C6-alkyl; and A and B are independently selected from R6-C(O)-(NH)-(CH(R5))- C(O)- and R6-C(O)- wherein at each occurrence R6 is independently selected from R7-N(C1-to-C6-loweralkyl)-, R7-O- and R7-S- wherein R7 is heterocyclic or (heterocyclic)-C1-to-C6-alkyl and at each occurrence R5 is independently selected from C1-to-C6-loweralkyl; or a pharmaceutically acceptable salt, thereof. Also disclosed are a composition use and kit for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.

公开(公告)号：DK1560811T3

公开(公告)日：2007-12-10

申请号：DK03774478

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  MICHMERHUIZEN MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：PT1560811E

公开(公告)日：2007-11-14

申请号：PT03774478

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： STEWART KENT D ,  SHAM HING L ,  MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  MICHMERHUIZEN MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SZCZEPANKIEWICZ BRUCE G

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

公开(公告)号：DK1339695T3

公开(公告)日：2006-07-31

申请号：DK01273519

申请日：2001-11-30

Applicant: ABBOTT LAB

Inventor： CLAIBORNE AKIYO K ,  GWALTNEY STEPHEN L II ,  LI TOMGMEI ,  MANTEI ROBERT A ,  ROCKWAY TODD W ,  TONG YUNSONG ,  WANG GARY T ,  WANG XILU ,  WANG WEIBO ,  HASVOLD LISA A ,  LI QUN ,  LIN NAN-HORNG ,  SHAM HING L ,  SULLIVAN GERARD M ,  WANG LE

IPC: C07D233/64 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/4709 ,  A61P35/00 ,  A61P43/00 ,  C07D233/54 ,  C07D277/20 ,  C07D277/30 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.

公开(公告)号：PT1200412E

公开(公告)日：2004-04-30

申请号：PT00950584

申请日：2000-07-21

Applicant: ABBOTT LAB

Inventor： WANG LE ,  LI QUN ,  SHAM HING L ,  WOODS KEITH W

IPC: C07D233/64 ,  A61K31/4164 ,  A61P35/00 ,  A61P43/00 ,  C07D233/54

公开(公告)号：AU2003282800A1

公开(公告)日：2004-04-08

申请号：AU2003282800

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： SZCZEPANKIEWICZ BRUCE G ,  MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  FEENSTRA MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D

IPC: A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  C07D207/00

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：BR0112028A

公开(公告)日：2004-02-17

申请号：BR0112028

申请日：2001-11-30

Applicant: ABBOTT LAB

Inventor： CLAIBORNE AKIYO K ,  GWALTNEY STEPHEN L II ,  HASVOLD LISA A ,  LI QUN ,  LI TOMGMEI ,  LIN NAN-HORNG ,  MANTEI ROBERT A ,  ROCKWAY TODD W ,  SHAM HING L ,  SULLIVAN GERARD M ,  TONG YUNSONG ,  WANG GARY T ,  WANG LE ,  WANG XILU ,  WANG WEIBO

IPC: A61K31/4164 ,  A61K31/4178 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/4709 ,  A61P35/00 ,  A61P43/00 ,  C07D233/54 ,  C07D233/64 ,  C07D277/20 ,  C07D277/30 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.